首页> 外文期刊>Open Journal of Anesthesiology >Use of Inhaled PGE1 to Improve Diastolic Dysfunction, LVEDP, Pulmonary Hypertension and Hypoxia in ARDS—A Randomised Clinical Trial
【24h】

Use of Inhaled PGE1 to Improve Diastolic Dysfunction, LVEDP, Pulmonary Hypertension and Hypoxia in ARDS—A Randomised Clinical Trial

机译:吸入PGE1改善ARDS的舒张功能障碍,LVEDP,肺动脉高压和低氧的一项随机临床试验

获取原文
           

摘要

Introduction: We wished to see the effects of inhaled PGE1 on diastolic dysfunction, left ventricular end diastolic pressure (LVEDP), pulmonary hypertension and hypoxia in ARDS patients. Methods: This is a randomized, prospective, clinical trial conducted in the main adult intensive care unit of a tertiary care University hospital. A total of 67 patients were recruited. Inclusion criteria included all adult patients with a P/F ratio 35 mmHg on Pulmonary artery catheter or suspected on clinical grounds. A transthoracic echo was performed to record the diastolic function, LVEDP and Pa pressures. Subsequently patients were randomized by a block computerized randomization to either cases (n = 34) or controls (n = 33). Cases received nebulised PGE1 over 30 minutes in the ICU and normal saline was administered to controls blindly. Following this the echo and arterial blood gases were repeated. Our primary outcomes were an improvement in diastolic function and P/F ratio of greater than 20% and a decrease in pulmonary pressure and LVEDP of >20%. Results: At baseline, mean diastolic dysfunction was grade II, with a mean LVEDP of >15 and the PaO2/FiO2 ratio was 148.38 ± 60.05 with a mean pulmonary artery pressure of 81.35 ± 16.91. Inhaled PGE1 was followed by an improvement in diastolic dysfunction (grade I, p = 0.001) with a resulting improvement in LVEDP (12 +/? 2, p = 0.001) as well as Pa pressures (97.09 ± 30.06, p = 0.04) and a non significant improvement in PaO2/FiO2 ratio (161.45 ± 77.52, p = 0.21). There were no side effects observed in any patients. Conclusion: Our study shows that there is a significant improvement in diastolic dysfunction, LVEDP and Pa pressures after administration of nebulised PGE1, and an improvement although non-significant in hypoxia in ARDS patients. The trial was registered with Clinicaltrials.gov (NCT00314548) and funded by the Pakistan medical research council.
机译:简介:我们希望看到PGE1吸入对ARDS患者的舒张功能障碍,左心室舒张末期压力(LVEDP),肺动脉高压和低氧的影响。方法:这是在三级护理大学医院主要成人重症监护室进行的一项随机,前瞻性临床试验。总共招募了67名患者。纳入标准包括肺动脉导管上P / F比为35 mmHg的所有成年患者或因临床原因而怀疑的成年患者。经胸腔回声记录舒张功能,LVEDP和Pa压力。随后,通过区组计算机随机化将患者随机分为病例(n = 34)或对照组(n = 33)。病例在ICU中经过30分钟接受了雾化的PGE1,并盲目地向对照组注射生理盐水。此后,重复回声和动脉血气。我们的主要结局是舒张功能改善,P / F比大于20%,肺压和LVEDP降低> 20%。结果:在基线时,平均舒张功能障碍为II级,平均LVEDP> 15,PaO2 / FiO2比为148.38±60.05,平均肺动脉压为81.35±16.91。吸入PGE1后舒张功能障碍改善(I级,p = 0.001),LVEDP改善(12 + /?2,p = 0.001),Pa压力(97.09±30.06,p = 0.04)和PaO2 / FiO2比例无明显改善(161.45±77.52,p = 0.21)。在任何患者中均未观察到副作用。结论:我们的研究表明,雾化的PGE1给药后,舒张功能障碍,LVEDP和Pa压力有显着改善,而ARDS患者的低氧改善明显,但无明显改善。该试验已在Clinicaltrials.gov(NCT00314548)上注册,并由巴基斯坦医学研究理事会资助。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号